The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...
The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.
When I first told my dentist about the Feno Smartbrush, eyebrows were raised. “Don’t use that,” she quipped as I explained the concept of Feno’s rather revolutionary approach to dental ...
Fewer than 10% of children or adolescents with peanut allergy passed a desnsitiaztion food challenge after receiving dupilumab for 24 weeks. Image: Adobe Stock “The impact of the findings for ...
The institute has now introduced Cardiopulmonary Exercise Testing (CPET) and Exhaled Nitric Oxide (FeNO) estimation in the outpatient department (OPD), further strengthening its commitment to high ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Dupilumab vs conventional AD therapies had less risk for anxiety, depression, and adjustment and sleep disorders, especially among Black patients. Patients with atopic dermatitis (AD) who were ...
They collected skin tape strips (STS) from the lesional and non-lesional skin of 20 patients with AD and 20 healthy volunteers (HV) over 16 weeks of dupilumab treatment. STS extracts were analyzed ...
In 2025, EOS could reach a maximum price of $1.04 and an average price of $0.867. By 2028, the EOS price value can reach a maximum of $2.78. The EOS price in 2031 could reach a maximum possible level ...
The current price of EOS (EOS) is $0.598889, as of February 8, 2025. Over the last 24 hours, the price has moved by 0.9%, with a change of -0.24% in the past hour. For longer-term performance, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results